Bio-Rad Receives Frost & Sullivan’s 2005 Product Innovation Award for In Silico ADME/Tox
Bio-Rad Laboratories, Inc. announced today that it has received Frost & Sullivan’s 2005 ADME/Tox Informatics Product Innovation Award. This award is presented annually to one company that exhibits excellence in new products and technologies within its industry. Frost & Sullivan selects the award recipient based on market participant interviews, end-user surveys, and extensive secondary research. The recipient company must also demonstrate innovation by launching a broad line of emerging products and technologies.
Dr. Amarpreet Dhiman, Industry Analyst, Frost & Sullivan Drug Discovery & Diagnostic Technologies Group, UK commented, “As the recipient of the 2005 Frost & Sullivan Product Innovation Award, Bio-Rad Laboratories, Inc. is commended for its success in developing innovative ADME/Tox solutions that bridge the technology gap between downstream and upstream systems.”
He continued, “The company’s pioneering, all purpose, fully integrated KnowItAll(R) ADME/Tox Edition suite with ADME/Tox Informatics tools reduces the time and cost involved in drug discovery and development. This multi-powerful suite facilitates assessment of the ADME/Tox profiles of potential lead compounds in the initial phases of drug discovery. Bio-Rad Laboratories’ clear understanding of end user needs coupled with its dedication to address such needs with a technologically advanced product portfolio, therefore makes it a worthy recipient of this award.”
Gregory M. Banik, Ph.D., General Manager of Bio-Rad’s Informatics Division remarked, “We are tremendously honored to again be the recipient of such a prestigious award. By combining partnering technologies with Bio-Rad’s award-winning software environment, the KnowItAll system has made a clear mark in the drug discovery community. We thank Frost & Sullivan for this recognition. We would also like to extend our gratitude to our development team and the partners with whom we have worked to make this product the success that it is.”
Bio-Rad’s KnowItAll Informatics System for in silico ADME/Tox offers a complete suite of tools for the computer-based prediction of a potential drug’s ADME/Tox profile, including the one of the largest collections of predictive models, applications to build and validate predictive models, experimental ADME/Tox data, and integrated tools for chemical structure handling, data management, and reporting.
About ADME/Tox Prediction
Within drug discovery, most failed compounds have problems associated with their Absorption, Distribution, Metabolism, Excretion, or Toxicity (ADME/Tox) profile. Virtual, or in silico ADME/Tox prediction is used to evaluate the ADME/Tox profile of a compound, even before it is synthesized, in order to eliminate poor drug candidates early on in the drug discovery cycle.
About Bio-Rad
Bio-Rad’s Informatics Division ( http://www.informatics.bio-rad.com ) specializes in state-of-the-art software and database solutions for the pharmaceutical, biotech, and chemical industries. Bio-Rad is the leading publisher of fully verified spectral databases, cheminformatics, spectroscopy software, and decision support systems for drug discovery. The company’s award-winning KnowItAll Informatics System offers a fully integrated environment with flexible, expandable software and database solutions for spectroscopy (MS, NMR, IR, Raman, spectral data management), cheminformatics, in silico ADME/Tox prediction, and lead optimization.
Bio-Rad Laboratories, Inc. ( http://www.bio-rad.com ) is a multinational manufacturer and distributor of life science research, clinical diagnostics, and informatics products. It is based in Hercules, California, and serves more than 70,000 research and industry customers worldwide through a network of more than 30 wholly owned subsidiary offices.
